Research programme: cytokine receptor antagonists - Trillium Therapeutics Inc
Alternative Names: Cytokine receptor antagonists research programme - Trillium Therapeutics IncLatest Information Update: 29 Nov 2021
At a glance
- Originator St. Justine Hospital; University of Montreal
- Developer Trillium Therapeutics
- Class
- Mechanism of Action Cytokine modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Inflammation
Most Recent Events
- 17 Nov 2021 Trillium Therapeutics Inc has been acquired by Pfizer
- 12 Feb 2013 Discontinued - Preclinical for Inflammation in Canada (unspecified route)
- 29 May 2007 No development reported - Preclinical for Inflammation in Canada (unspecified route)